Is there any place for salmon calcitonin in prevention of postmenopausal bone loss?

Publisher Website
Google Scholar
Abstract
Introduction Postmenopausal bone loss and subsequent osteoporosis (OP) are consequences of a change in bone turnover leading to an imbalance between resorption and formation1. One of the most effective ways of preventing postmenopausal bone loss, or at least of slowing its rate, is to use estrogen replacement therapy (ERT), either alone or in combination with a progestogen2,3. However, the dose of estrogen required to produce a net gain of bone is much higher than that required to control other postmenopausal symptoms4, hence the risk of adverse effects is greater, which makes ERT unsuitable for many postmenopausal women. For a large subset of postmenopausal women there is thus an urgent need for an alternative to ERT in order to prevent excessive bone loss.